ArticleInfluenza and other respiratory viruses2026
Navigating the Future of Respiratory Infections: Key Insights From International Congress in Singapore, 17-20 September 2025.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 8th International Society for Respiratory Viruses (ISRV) Antiviral Group Conference, held jointly with the 3rd International Meeting on Respiratory Pathogens in Singapore (17-20 September 2025), examined evolving approaches to prevention and management of respiratory infections. This report summarizes the major themes and perspectives that emerged across the meeting.
methodsWe reviewed plenary sessions, thematic symposia and panel discussions and synthesized recurring concepts relevant to clinical practice and preparedness. Discussions were organized into key domains, including therapeutics, host response, vaccination, surveillance, diagnostics and research infrastructure.
resultsPresentations highlighted the development of long-acting and broadly active antivirals, interest in combination therapy and early treatment, and increasing recognition that inflammatory host responses contribute substantially to disease severity. Advances in vaccines targeting conserved viral components and long-acting monoclonal antibodies were discussed, along with the growing role of adaptive platform trials and harmonized clinical endpoints. A recurring theme was the transition from pathogen-centred management to a broader framework incorporating host responses. Speakers also emphasized integrated surveillance using genomic sequencing, metagenomics and rapid point-of-care diagnostics within a One Health framework addressing zoonotic spillover.
conclusionsThe meeting illustrated how clinical care, translational science and public health preparedness are becoming increasingly interconnected. Sustained investment in surveillance systems, clinical trial platforms and access to therapeutics will be necessary to translate scientific progress into routine care and to strengthen readiness for future epidemics and pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.